New government drug repurposing programs: Opportunities and uncertainties

Johnathan Liddicoat; Ashleigh  Hamidzadeh; Kathleen Liddell; Marco   Schito; David  Simon; Mateo Aboy; Timo Minssen

doi:10.1126/scitranslmed.adl0998

New government drug repurposing programs: Opportunities and uncertainties

Johnathan Liddicoat^*, Ashleigh Hamidzadeh , Kathleen Liddell, Marco Schito, David Simon, Mateo Aboy, Timo Minssen

^*Corresponding author for this work

Center for Advanced Studies in Bioscience Innovation Law

Research output: Contribution to journal › Journal article › Research › peer-review

2 Citations (Scopus)

Abstract

Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies

Original language	English
Article number	eadl0998
Journal	Science Translational Medicine
Volume	16
Issue number	753
Number of pages	4
ISSN	1946-6234
DOIs	https://doi.org/10.1126/scitranslmed.adl0998
Publication status	Published - 2024

Bibliographical note

Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.

Keywords

Faculty of Law
Government Programs
drug R&D
new uses
drug repurposing
Public private partnership
Emperical legal studies

Access to Document

10.1126/scitranslmed.adl0998Licence: Unspecified

Cite this

@article{ecb193fe331840e1a11480d5d8ad6d2f,

title = "New government drug repurposing programs: Opportunities and uncertainties",

abstract = "Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies",

keywords = "Faculty of Law, Government Programs, drug R&D, new uses, drug repurposing, Public private partnership, Emperical legal studies",

author = "Johnathan Liddicoat and Ashleigh Hamidzadeh and Kathleen Liddell and Marco Schito and David Simon and Mateo Aboy and Timo Minssen",

note = "Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.",

year = "2024",

doi = "10.1126/scitranslmed.adl0998",

language = "English",

volume = "16",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "american association for the advancement of science",

number = "753",

}

TY - JOUR

T1 - New government drug repurposing programs

T2 - Opportunities and uncertainties

AU - Liddicoat, Johnathan

AU - Hamidzadeh , Ashleigh

AU - Liddell, Kathleen

AU - Schito, Marco

AU - Simon, David

AU - Aboy, Mateo

AU - Minssen, Timo

N1 - Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.

PY - 2024

Y1 - 2024

N2 - Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies

AB - Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies

KW - Faculty of Law

KW - Government Programs

KW - drug R&D

KW - new uses

KW - drug repurposing

KW - Public private partnership

KW - Emperical legal studies

U2 - 10.1126/scitranslmed.adl0998

DO - 10.1126/scitranslmed.adl0998

M3 - Journal article

C2 - 38924430

SN - 1946-6234

VL - 16

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 753

M1 - eadl0998

ER -